AÉMA-GROUPE
On 30 September 2021, Aéma Groupe acquired Aviva France, after obtaining the necessary authorisations from the regulatory authorities. This large-scale operation places Aéma Groupe in the 5th position of the French insurance industry. It concretises the original ambition of Macif and Aésio Mutuelle, founders of Aéma Groupe, to build a leading mutual insurance group that now protects over 11 million French people.
‘The creation of Aéma Groupe was the culmination of the ambition of two companies, Aésio Mutuelle and Macif, to join forces to build a large-scale mutual insurance group capable of offering the broadest possible protection to its policyholders, both today and tomorrow. The acquisition of Aviva France is the first phase in this process. This transaction, which was completed in less than a year and ahead of schedule, demonstrates our ability to build a strong and innovative player that meets the growing needs of society as a whole’. - Adrien Couret - Managing Director of Aéma Groupe.
An acquisition that confirms the relevance of the Aéma Groupe model
Thanks to its economic significance and strategic importance, this transaction brings Aviva France under the French mutual insurance umbrella. Aéma Groupe thereby demonstrates its ability to expand and serve a wider range of policyholders (individuals, professionals, self-employed persons, companies) with a comprehensive range of solutions. This multi-brand, multi-network, multi-business group is strengthening its positions in all areas of insurance thanks to its complementary expertise. As a resolutely mutualist group, it will also make the voice of its members and customers heard in the public debate on social issues relating to protection and retirement.
‘We are very proud to welcome this fine company as the third pillar of Aéma Groupe, alongside Macif and Aésio. With Aviva France, we are creating a leading French mutual insurance group. From now on, Aviva France, supported by its 4,500 employees, will keep growing within our common structure. It will accomplish this while retaining its identity and its specific characteristics, with the same determination to provide increasingly relevant and sustainable insurance solutions to its 3 million policyholders, including the 760,000 members of AFER’. - Pascal Michard , Chairperson of Aéma Groupe.
New management for Aviva France
Following the acquisition, Aviva France has formed its new board of directors, which has appointed Jean-Philippe Dogneton as Chairperson and Philippe-Michel Labrosse as Chief Executive Officer of Aviva France.
‘In addition to enriching our diversity, the arrival of Aviva France within our group will enhance our diversity and gives us new responsibilities vis-à-vis the policyholders, the members and the clients we deal with on a daily basis. This acquisition will enhance the synergies of skills and expertise and the mutual know-how to enrich our offers and services. We are extremely proud and happy to welcome the Aviva France teams who share our values of solidarity and commitment’. - Jean-Philippe Dogneton , Assistant Managing Director of Aéma Groupe, Managing Director of Macif and new Chairperson of Aviva France
‘ I would like to thank the Board of Directors of Aviva France for trusting me to anchor the company to Aéma Groupe, its new parent company, and to keep it on the path to success with the support of all its employees, networks and partners’. Philippe-Michel Labrosse – Managing Director of Aviva France.
Aviva France will be rebranded with a gradual roll-out.
This acquisition involved Lazard as lead M&A advisor, Credit Suisse as financing and M&A advisor, White & Case LLP as legal advisor, Kearney for strategy, EY for accounting and financial analysis, Prim'Act for actuarial services, and Fromont Briens for employment law.
–––––––––––––––––––––––––––––––––––––––––––––––––
Key figures:
- 14.5 billion euro in turnover;
- 18,000 employees;
- 11 million policyholders;
- Property & Casualty: 5 billion euro in premium income;
- Health & Personal Protection: 3 billion euro in premium income;
- Life business: 6.5 billion euro in premium income;
- Assets under management: 195 billion euro.
Leading positions in the business lines:
- 5th largest insurance company in France;
- 2nd largest player in home and car insurance;
- 3rd largest mutual group in individual and group health;
- 5th largest player in life insurance;
- 6th largest player in asset management.
About Aéma Groupe
Aéma is the mutual insurance group formed by the merger of Aésio Mutuelle and Macif.
With more than 11 million policyholders, it employs 18,000 people
and generates a turnover of 14.5 billion euros in France.
Aéma Groupe envisions a fairer and more humane world every day by making foresight a central part of the relationship with its members, policyholders and corporate clients.
Find out more: aemagroupe.fr
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005554/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
